Low-GWP Medical Propellants Market
完整報告名稱與涵蓋範圍
Low-GWP Medical Propellants Market Size, Share & Trends Analysis Report, By Propellant Type (HFO-1234ze(E), HFA-152a, Legacy HFA-134a and HFA-227ea (Transition Reference)), By Grade (Pharmaceutical Grade Propellants, Technical and Pilot Grades), By Application (Asthma and COPD Metered Dose Inhalers, Other Medical Aerosols and Topical Sprays), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The low-GWP medical propellants market covers pharmaceutical-grade hydrofluoroolefin and low-global-warming-potential hydrofluorocarbon gases used to propel metered dose inhalers and other medical aerosols, principally HFO-1234ze(E) and HFA-152a, with legacy HFA-134a and HFA-227ea analysed as the transition baseline. Inhaler components, industrial refrigerant grades and non-medical aerosol propellants are excluded.
The transition is driven by fluorinated gas regulation in Europe and the United States that phases down high-GWP hydrofluorocarbons, by the carbon reduction commitments of health systems, which identify inhalers as a leading pharmaceutical emission source, and by originator programs that have already submitted low-GWP inhaler applications. Propellant suppliers must deliver pharmaceutical-grade purity, extensive toxicology and stability data, dedicated production capacity and drug master files, and they face the challenge that HFA-152a is flammable and HFO-1234ze(E) has different solvency, both requiring formulation and filling changes. Supply security, price premiums over legacy propellants and the timing of regulatory approvals for reformulated inhalers determine how quickly the substitution proceeds.
Europe leads regulatory pressure, North America follows, and India and China are significant both as propellant producers and as inhaler manufacturing hubs. Competition involves global fluorochemical companies with pharmaceutical-grade programs and Asian fluorochemical producers scaling medical grades.
The InsightAce study includes revenue forecasts in US$ for all propellant type, grade, application and end user and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Low-GWP Medical Propellants Market Snapshot
Chapter 4. Global Low-GWP Medical Propellants Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Propellant Type Estimates & Trend Analysis
5.1. Propellant Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Propellant Type:
5.2.1. HFO-1234ze(E)
5.2.2. HFA-152a
5.2.3. Legacy HFA-134a and HFA-227ea (Transition Reference)
Chapter 6. Market Segmentation 2: By Grade Estimates & Trend Analysis
6.1. Grade & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Grade:
6.2.1. Pharmaceutical Grade Propellants
6.2.2. Technical and Pilot Grades
Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis
7.1. Application & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
7.2.1. Asthma and COPD Metered Dose Inhalers
7.2.2. Other Medical Aerosols and Topical Sprays
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Respiratory Pharmaceutical Companies
8.2.2. Inhaler CDMOs
8.2.3. Generic Inhaler Manufacturers
Chapter 9. Low-GWP Medical Propellants Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Honeywell International Inc.
11.2. Koura (Orbia)
11.3. The Chemours Company
11.4. Daikin Industries, Ltd.
11.5. Arkema S.A.
11.6. SRF Limited
11.7. Zhejiang Juhua Co., Ltd.
11.8. Sinochem Lantian Co., Ltd.
11.9. Linde plc
11.10. Air Liquide S.A.
11.11. Navin Fluorine International Limited
11.12. Gujarat Fluorochemicals Limited
11.13. Solvay S.A. (Syensqo)
11.14. AstraZeneca plc (Propellant Development Partnerships)
11.15. Chiesi Farmaceutici S.p.A.
圖表清單 List of Tables & Figures
Table 1. Global Low-GWP Medical Propellants Revenue Forecast by Propellant Type, 2026-2035 (US$ Mn)
Figure 1. Global Low-GWP Medical Propellants Market Snapshot, 2026 & 2035
Table 2. Global Low-GWP Medical Propellants Revenue Forecast by Grade, 2026-2035 (US$ Mn)
Figure 2. Global Low-GWP Medical Propellants Market Share by Grade, 2026 & 2035
Table 3. Global Low-GWP Medical Propellants Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 3. Global Warming Potential and Physical Property Comparison of Medical Propellants
Table 4. Global Low-GWP Medical Propellants Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Fluorinated Gas Phase-Down Regulation and Its Effect on Inhaler Propellant Demand, 2025-2035
Table 5. North America Low-GWP Medical Propellants Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Low-GWP Medical Propellants Growth Opportunity Analysis
Table 6. Europe Low-GWP Medical Propellants Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Pharmaceutical-Grade Propellant Capacity and Supply Chain by Producer
Table 7. Asia Pacific Low-GWP Medical Propellants Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Low-GWP Medical Propellants Market Participants
Table 8. Latin America and Middle East & Africa Low-GWP Medical Propellants Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們